Chinese CAR-T player books a megaround to drive bustling cell therapy portfolio through the clinic

Kyle Blankenship

China has quickly emerged as a major driver of oncology R&D in recent years, particularly in cell therapies where the potential for cheaper development has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chinese CAR-T player books a megaround to drive bustling cell therapy portfolio through the clinic

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Chi­nese CAR-T play­er books a megaround to dri­ve bustling cell ther­a­py port­fo­lio through the clin­ic

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Chinese CAR-T player books a megaround to drive bustling cell therapy portfolio through the clinic